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Background: Most programs favor single lung transplantation for emphy- 
sema. However, this is controversial, and we have favored bilateral ung 
transplantation, confining single lung transplantation mainly to use in 
older patients and those of small stature. Methods: A retrospective analysis 
was done of 119 consecutive lung transplantation procedures for emphy- 
sema at Barnes Hospital between 1989 and 1994 (50 single lung, 69 
bilateral ung transplants) to (1) identify outcome differences between the 
two groups and (2) define the appropriate role of these two procedures. 
Results: The single lung transplantation group was older and had a higher 
proportion of female patients. However, baseline pulmonary function 
(forced expiratory volume in 1 second), arterial oxygen tension, and 
exercise tolerance (6-minute walk distance) w re similar. After transplan- 
tation, 90-day mortality (single lung transplantation 10% versus bilateral 
lung transplantation 7.2%; p = 0.74) and duration of mechanical ventila- 
tion, intensive care unit stay, and hospitalization were similar. Both groups 
achieved a significant and sustained improvement in forced expiratory 
volume, arterial carbon dioxide tension, arterial oxygen tension, and 
exercise tolerance within 3 months. However, the improvements in forced 
expiratory volume, arterial oxygen tension, and exercise tolerance were 
consistently significantly better in recipients of bilateral transplants at and 
beyond 6 months. Obliterative bronchiolitis was equally prevalent in both 
groups. Survival was similar but showed a trend toward better late survival 
in recipients of bilateral transplants (5-year actuarial survival: bilateral 
lung transplantation 53% versus single lung transplantation 41%). Conclu- 
sions: We conclude that (1) both procedures are satisfactory options in 
emphysema, producing durable results; (2) bilateral ung transplantation 
is not associated with increased operative mortality or morbidity and 
achieves uperior improvements in spirometry findings, oxygenation, exer- 
cise tolerance, and possibly late survival; and (3) the superior improve- 
ments in function (and late survival) after bilateral ung transplantation 
may be attributed to the presence of more pulmonary reserve after the onset 
of obliterative bronchiolitis. (J Thorac Cardiovasc Surg 1996;112:1485-95) 
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L ung transplantation is an established treatment modality for end-stage obstructive lung disease, 
and emphysema now constitutes the most common 
indication for lung transplantation worldwide. 1The 
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traditional paradigm held that single lung transplan- 
tation (SLT) was unworkable in advanced emphy- 
sema. Consequently, considerable initial success was 
encountered in the use of bilateral lung replacement 
for emphysema during the mid-1980s. 2 This was first 
accomplished with use of the en bloc double lung 
transplantation technique, 2 although this was later 
supplanted by the bilateral sequential lung trans- 
plantation (BLT) procedure. 3 However, substantial 
numbers of published reports are now available that 
have demonstrated first the clinical feasibility of 
SLT for emphysema 4-6 and later the medium-term 
functional results with this approach. 7'8 Several 
reports have compared the early outcomes of single 
versus bilateral lung replacement in emphysema. TM 
There remains considerable controversy regarding 
the ideal application of SLT and BLT in patients 
with obstructive lung disease, and to date no long- 
term follow-up studies with comparison of late 
results have been available. The purpose of this 
study was to review our experience with SLT and 
BLT for obstructive lung disease at Barnes Hospital, 
to try to determine which of these represents the 
superior transplantation ption. 
Patients and methods 
We retrospectively analyzed 119 consecutive cases of 
SLT and BLT done for obstructive lung disease (chronic 
obstructive pulmonary disease caused by cigarette smok- 
ing or al-antitrypsin deficiency emphysema) in the Barnes 
Hospital/Washington U iversity lung transplantation pro- 
gram between July 1, 1988, and December 31, 1994. (Two 
patients who underwent en bloc double lung transplanta- 
tion because of obstructive lung disease early during the 
study interval were deliberately excluded from the analy- 
sis.) Technical aspects of the donor 12 and recipient 13' 14 
operative procedures and details regarding immunosup- 
pression protocols 15 and posttransplantation f llow-up 
and management 16 have been reported elsewhere. Fol- 
low-up was completed on July 1, 1995 (the date of 
beginning the analysis) or at the time of the recipient's 
death. Follow-up was complete in all recipients and 
ranged from 7 to 64 months. 
Our general criteria for choosing between SLT and 
BLT are as follows. BLT is used in younger patients (age 
generally younger than 50 to 55 years), in patients of large 
stature (height more than 5 feet, 8 inches), and/or in 
patients with emphysema accompanied bybullous change. 
SLT is used in older patients (for example, older than 55 
years) or in those of smaller stature (height less than 5 
feet, 6 inches). 
Preoperative parameters evaluated. The following pa- 
rameters were reported for all recipients in the two groups 
(SLT and BLT): (1) age and sex distribution, (2) diagnosis 
(chronic obstructive pulmonary disease, C~l-antitrypsin 
deficiency emphysema), (3) pulmonary function test re- 
sults (forced expiratory volume in 1 second [FEV~] as a 
percentage ofpredicted), (4) arterial blood gas values on 
room air (arterial carbon dioxide tension [Paco2] and 
oxygen tension [Pao2] in millimeters of mercury), and (5) 
exercise tolerance (evaluated in a standard 6-minute walk 
test as previously described)? 
Operative parameters evaluated. The following param- 
eters pertaining to the operative course were evaluated: 
(1) operation performed (SLT or BLT; for SLT, right or 
left), (2) graft ischemic time (in minutes; for BLT, the 
ischemic time was considered to be that of the second 
allograft inserted), and (3) use of cardiopulmonary b - 
pass. 
Postoperative parameters evaluated. The following pa- 
rameters pertaining to the early and late postoperative 
periods were evaluated for all recipients in each group. 
First, early postoperative course evaluation included 90- 
day mortality, days of mechanical ventilation, days in the 
intensive care unit, and days in the hospital. Second, 
Pulmonary function test results (FEV1), arterial blood gas 
levels (Paco2, Pao2), and exercise tolerance (6-minute 
walk test) were evaluated for all recipients at 3 and 6 
months after operation and then annually until the end of 
the follow-up interval or until the time of the recipient's 
death. Third, Recipients in each group were evaluated for 
the development of bronchiolitis obliterans yndrome 
(BOS) with the use of previously described criteria. 17 
Briefly, BOS was diagnosed if there was a sustained and 
significant fractional decline in FEV~ (less than 80% of a 
previously established postoperative baseline value) more 
than 3 months beyond the date of the transplantation r if 
obliterative bronchiolitis was documented pathologically. 
Fourth, actuarial survival was determined by the Kaplan- 
Meier method. 
Data analysis. Whenever applicable, data are pre- 
sented as mean plus or minus standard error of the mean. 
Statistical comparison of values between the SLT and 
BLT groups was done as follows: tabular data with 
Fisher's exact test; paired data with the paired t test; 
Kaplan-Meier survival data with the Mantel-Haenszel 
test; and the remainder with repeated-measures analysis 
of variance (multivariate comparisons were done with 
contrast). Values were considered significantly different 
when the p value was less than 0.05. 
Results 
Fifty (42%) of the 119 patients underwent SLT, 
and 69 (58%) of 119 underwent BLT. In the SLT 
group, 19 (38%) of 50 received a right lung allograft, 
whereas 31 (62%) of 50 received a left lung allo- 
graft. 
Comparison of preoperative parameters. Recip- 
ients in the SLT group were older (SLT 55 _+ 1 years 
vs BLT 49 _+ 1 years; p < 0.001). Also, the SLT 
group showed a higher percentage of female pa- 
tients (SLT 68% women vs BLT 42% women; p = 
0.009) and patients with chronic obstructive pul- 
monary disease (SLT 82% chronic obstructive 
pulmonary disease and 18% oq-antitrypsin defi- 
ciency emphysema vs BLT 54% chronic obstructive 
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Fig. 1. Paco 2 in millimeters of mercury for recipients in both groups preoperatively (Pre-op) and during 
posttransplantation f llow-up. All data are shown as mean _+ standard error of mean. *, Significant versus 
preoperative alue; +, significant versus SLT value at corresponding time. 
Table I. Comparison of preoperative and operative parameters between groups 
Preoperative Operative 
Age (YO Gender distribution Diagnosis Ischemic time (min) Use of CPB 
SLT 55 -+ 1 M 32%, F 68% COPD 82%, ATDef 18% 267 _+ 9 1/50 (2%) 
p Value <0.001 0.009 0.002 <0.0001 0.002 
BLT 49 -- 1 M 58%, F 42% COPD 54%, ATDef 46% 369 _+ 10 14/69 (20%) 
Data shown as mean -+ standard error of mean where applicable. CPB, Cardiopulmonary b pass; M, male; F, female; COPD, chronic obstructive pulmonary 
disease; ATDef, %-antitrypsin deficiency emphysema. 
pulmonary disease and 46% %-antitrypsin defi- 
ciency emphysema; p = 0.002) (Table I). The mean 
preoperative Pac% level was significantly higher in 
the SLT group (SLT 47.6 _+ 1.5 mm Hg vs BLT 
44.1 _+ 0.9 mm Hg;p  = 0.038) (Fig. 1). There was no 
difference between the SLT and BLT groups with 
respect o preoperative FEV 1 value (SLT 17.6% + 
0.6% of predicted vs BLT 16.9% _+ 0.5% of pre- 
dicted; p = 0.369), Pao 2 (SLT 54.1 _+ 1.9 mm Hg vs 
BLT 56.7 ± 1.3 mm Hg; p = 0.261), or distance 
covered in the 6-minute walk test (SLT 980 _+ 46 
feet versus BLT 993 _+ 49 feet; p = 0.876) (Figs. 2 
through 4). 
Comparison of operative parameters. The mean 
graft ischemic time was longer in the BLT group 
(BLT 369 ± 10 minutes vs SLT 267 + 9 minutes; 
p < 0.0001). Also, cardiopulmonary bypass was 
required with significantly higher frequency in the 
BLT group (BLT 20% vs SLT 2%;p = 0.002, Table 
I), in every case because of poor first graft function 
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Fig. 2. FEV a as percent of predicted for recipients in both groups preoperatively (Pre-op) and during 
posttransplantation follow-up. All data are shown as mean -+ standard error of mean. *, Significant versus 
preoperative alue; +, significant versus SLT value at corresponding time. 
(unsatisfactory hemodynamics or gas exchange). In 
only one patient in the SLT group was CPB required 
to repair an inadvertent laceration in the proximal 
left pulmonary artery. 
Comparison of early postoperative course. Table 
II summarizes the parameters relevant o the early 
postoperative course. There was no difference be- 
tween the SLT and BLT groups with respect to 
90-day mortality (SLT 10% vs BLT 7.2%;p -- 0.74). 
Duration of mechanical ventilation (BLT 3.9 _+ 1.0 
days vs SLT 2.2 _+ 0.3 days) and intensive care unit 
stay (BLT 5.0 _+ 1.0 days vs SLT 3.0 _+ 0.3 days) were 
both longer in the BLT group, although neither of 
these differences achieved significance (p = 0.108 
and 0.059, respectively). Duration of hospital stay 
was similar between groups (BLT 24.5 _+ 1.5 days vs 
SLT 23.4 + 1.8 days; p = 0.652). 
Comparison of late postoperative pulmonary func- 
tion, gas exchange, and exercise tolerance. A signifi- 
cant improvement in FEV1, Paco2, and Pao z values 
and in exercise tolerance was noted within 3 months 
after transplantation in both groups and was sustained 
throughout he period of late follow-up (Figs. 1 
through 4). The improvements in FEV1 and Pao2 
values were significantly better in the BLT group 
(compared with those in the SLT group) from 3 
months until 4 and 3 years after transplantation, 
respectively (Figs. 2 and 3). The improvement in 
exercise tolerance was significantly better in the BLT 
group at 6 months, and this superior improvement was 
maintained until 3 years after t ansplantation (Fig. 4). 
There was no difference between groups with respect 
to Paco 2 values throughout the period of late fol- 
low-up (Fig. 1). 
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Fig. 3. Pao 2 in millimeters of mercury for recipients in both groups preoperatively (Pre-op) and during 
posttransplantation follow-up. All data are shown as mean +- standard error of mean. *, Significant versus 
preoperative alue; +, significant versus SLT value at corresponding time. 
Development of BOS. The development of BOS 
is summarized in Table III. Recipients were consid- 
ered at risk for the development of BOS only if they 
survived at least 90 days after transplantation (64 
BLT recipients and 45 SLT recipients). BOS was 
more prevalent in the SLT group (SLT 23/45 [51%] 
vs BLT 21/64 [33%]); this difference approached but 
did not achieve significance (p = 0.079). Mortality in 
recipients with BOS did not differ between groups 
(SLT, 7 deaths in 23 recipients with BOS [30.4%] vs. 
BLT, 6 deaths in 21 [28.6%]; p = 1.00). 
Actuar ia l  surv iva l .  Actuarial survival curves for 
the SLT and BLT groups are shown in Fig. 5. The 
1-year survival was 88% after SLT and 84% after 
BLT. Survival was similar in both groups until 3 
years after transplantation (BLT 80% vs SLT 79%). 
Subsequently, survival declined in both groups, but 
tended to be better in the BLT group (4-year 
actuarial survival: BLT 73% vs SLT 51%; 5-year 
actuarial survival: BLT 53% vs SLT 41%). Although 
the 5-year actuarial survival appeared better in the 
BLT group, this difference did not achieve signifi- 
cance (p = 0.27). 
Discuss ion  
Emphysema has continued to be the fifth leading 
cause of death in the United States during the past 
couple of decades and now constitutes the most 
common indication for lung transplantation world- 
wide) However, the optimal ung transplantation 
procedure, single or bilateral lung replacement, 
continues to be a matter of debate. 
On the basis of significant improvements in sev- 
eral parameters including spirometry (FEVI), blood 
gas levels (Paco2, Pao2), and exercise endurance 
(6-minute walk distance), this study has shown that 
both SLT and BLT are satisfactory transplantation 
options in patients with end-stage mphysema. Our 
study has also shown that both SET and BLT 
produce xtremely durable results, inasmuch as the 
improvements in these parameters were sustained as 
late as 4 years after transplantation. To our knowl- 
edge, we report here the longest duration of fol- 
low-up in a single-institution comparison of SLT 
versus BLT for emphysema and provide late confir- 
mation of the medium-term follow-up data of Mal 
and colleagues 7 and Levine and associates. 8 Fur- 
1490 Sundaresan et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1996 
2000 
o 1750 - 
O 
7: 
< 
1500- 
1250 - 
f. 
Z 
I 
1000 -
750 
;, ..................... i+ i .................. / 
.... ~ ........................... • ..... + ............ I. 
T* ................. _L / "0  
.¢, .... + 
, ,  .,. 
/ r  T 
/ // 
O-- - -  SLT 
........ O ........ BLT 
I I I I I I I 
Pre-op 3 mos 6 mos 1 y 2 y 3 y 4 y 
TIME POINT 
Fig. 4. Distance in feet covered in standard 6-minute walk test for recipients in both groups preoperatively 
(Pre-op) and during posttransplantation follow-up. All data are shown as mean _+ standard error of mean. 
*, Significant versus preoperative alue; +, significant versus SLT value at corresponding time. 
Table II. Comparison of early postoperative outcome parameters between groups 
Duration of mechanical Duration of ICU stay Duration of hospital stay 
Death <90 days ventilation (days) (days) (days) 
SLT 5/50 (10%) 2.2 _+ 0.3 3.0 _+ 0.3 23.4 _+ 1.8 
p Va lue  0.74 0.108 0.059 0.652 
BLT  5/69 (7.2%) 3,9 + 1.0 5.0 -+ 1.0 24.5 -+ 1.5 
Data shown as mean -+ standard error of mean where applicable. ICU, Intensive care unit. 
thermore, transplantation procedures were accom- 
plished with an acceptably low early (90-day) mor- 
tality rate. The 90-day mortality rate did not exceed 
10% in either group. These figures compare favor- 
ably with mortality statistics for similar SLT and 
BLT groups reported in the International RegistryJ 
Data from the International Registry reveal that 
almost 80% of lung transplantation procedures 
done for emphysema in the international experience 
are SLTsJ We report here a different utilization of 
these two transplantation procedures and actually 
show a preference for BLT (42% SLT and 58% BLT 
in our experience). This obvious discrepancy with 
the international experience merits a comparison of 
our SLT and BLT groups. SLT recipients were older 
and predominantly had chronic obstructive pulmo- 
nary disease (82%). The higher percentage of 
women in the SLT group (68%) may have been a 
result of stature (see later discussion). The younger 
age of the recipients of BLT is partly explained on 
the basis of a higher proportion of patients with 
alphal-antitrypsin deficiency (46%), along with our 
unproven supposition of greater long-term durabil- 
ity of results with BET. 
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Our notion is that SLT is a simpler operation and 
is therefore well-suited to minimize potential oper- 
ative risks in older patients, in whom complications 
may be more frequent. We have also thought hat 
SLT is suitable in patients of smaller body habitus, 
in whom a satisfactory volume of lung allograft can 
be achieved with a single lung by deliberately over- 
sizing the donor by up to 20%. This size-matching 
strategy isgenerally more readily achieved in female 
patients. It is important to note, however, that 
although we determined these demographic differ- 
ences, the two groups were equivalent before oper- 
ation in terms of functional status, oxygenation, and 
exercise tolerance. 
The decision regarding the choice of SLT versus 
BLT in emphysema must be based on several con- 
siderations. The first of these relates to the technical 
complexity of the procedure. Intuitively, SLT is a 
much simpler transplantation option. The proce- 
dure should be short and technically straightfor- 
ward. Operative blood loss should be less and 
intraoperative hypotensive pisodes less frequent 
and less severe. The graft ischemic time should be 
shorter, thereby minimizing the incidence of early 
postoperative graft dysfunction. The necessity for 
cardiopulmonary bypass should be rare, and the 
potential need for postoperative inotropic and vaso- 
active agents should be minimal. In this study, we 
used graft ischemic time and use of cardiopulmo- 
nary bypass as major objective indicators of the 
"complexity" of the operation and, on this basis, 
confirmed the greater magnitude of the BLT proce- 
dure. We did not find a difference between groups 
with respect to either 90-day mortality (SLT 10% vs 
BLT 7.2%) or hospital mortality (SLT 6% vs BLT 
7.2%). Although there was a trend to longer dura- 
tion of mechanical ventilation and intensive care 
unit stay in the BLT group, neither of these differ- 
ences achieved significance, and ultimately the du- 
ration of hospital stay was similar. Therefore this 
study has not demonstrated that SLT is associated 
with lower operative or perioperative risks than BLT. 
Our failure to demonstrate the anticipated higher 
mortality in the BLT group may be partially accounted 
for by the younger status of the patients receiving BLT. 
However, although the majority of the BLT proce- 
dures were done in patients between 46 and 55 years 
old (40 cases), BLT was also done in patients between 
the ages of 56 and 60 years (8 cases compared with 18 
in the SLT group for this age range) and even in 
patients 61 years old or more (2 cases compared with 
6 SLT cases in this same age range). 
Table III. Prevalence of BOS and mortality in 
recipients with BOS in SLT and BLT groups 
SLT  BLT  
(iV = 50) p Value (N = 69) 
No. at risk for BOS 45 64 
Prevalence of BOS 23/45 (51%) 0.079 21/64 (33%) 
Mortality in recipients 7/23 (30.4%) 1.00 6/21 (28.6%) 
with BOS 
The scarcity of suitable donors continues to be the 
main factor limiting more widespread use of lung 
transplantation. This constitutes another consider- 
ation in favor of SLT for emphysema, in that this 
approach can potentially accomplish twice as many 
lung transplantations from the same number of 
donors. However, this rationale is only valid if both 
lungs in each multiple-organ donor satisfy the tra- 
ditional rigorous donor criteria. 12 This is illustrated 
somewhat in our SLT group. Forty-five donors 
yielded our 50 SLTs for emphysema and 19 other 
SLTs, for a total of 69 SLTs. However, an opposing 
argument in favor of BLT can be made on the basis 
of our recent report on the use of marginal donor 
lungs. 18 In that report, marginal donors were used as 
a means of expanding the limited donor pool, and 
this approach was not found to compromise satis- 
factory outcome. 18 Analysis of the most recent 52 of 
the 69 transplantations in our BLT group reveals 
that 27 (52%) of the 52 recipients of BLT received 
marginal donor lungs. Of note, 21 (78%) of these 27 
marginal donors were deemed marginal on the basis 
of poor oxygenation (Pao2 <300 mm Hg on inspired 
fraction of oxygen = 1.0 and 5 cm water positive 
end-expiratory pressure) or unsatisfactory chest ra- 
diograph (that is, containing infiltrates or contu- 
sions). With donors of such marginal status, SLT 
would rarely be possible. However, we have evolved 
to using both lungs from such marginal donors 
frequently in performing BLT in patients with em- 
physema with satisfactory outcomes as reported 
here. The specific aspects of BLT in emphysema 
that facilitate the use of such marginal grafts are (1) 
a large pleural space, usually devoid of adhesions, 
which facilitates rapid transplantation of the first 
graft and (2) use of the most marginal donor lung as 
the second graft. Thus our liberal use of such 
marginal donors in BLT for emphysema f cilitated 
the performance of 21 (30%) of our 69 BLT cases, 
as opposed to accomplishing no transplant at all. 
Is SLT equivalent to BLT in the long term? A 
number of parameters must be evaluated to answer 
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this question, including objective functional param- 
eters, the patients' subjective sense of improvement, 
the development of BOS, and late survival. On the 
basis of our data, both SLT and BLT produce 
significant improvement in all of the chosen objec- 
tive parameters (FEV], Paco2, Pao  2, and 6-minute 
walk distance); however, the improvements in FEV1 
value, oxygenation, and exercise tolerance were all 
better after BLT, and this superiority was sustained 
during late follow-up. Improvement in FEV z value 
was significantly better in the BLT group up to 4 
years after transplantation. The improvements in
Pao 2 level and 6-minute walk distance were signifi- 
cantly better after BLT until 3 years, and it is likely 
that the relatively smaller number of available mea- 
surements at 4 years was the reason that these 
differences did not achieve significance at this point. 
With respect to improvement in these selected 
parameters our findings confirm superiority of BLT 
over SLT, which was already demonstrated in pre- 
viously published short-term follow-up studies} ], 12 
However, an important issue, the recipients' ubjec- 
tive sense of improvement after the transplantation, 
was not specifically addressed in this study. 
In a previous report we showed that BOS even- 
tually affects at least 50% of lung transplant recipi- 
ents and that this entity is. equally prevalent in all 
subgroups of lung allograft recipients, without re- 
gard for the underlying diagnosis or the type of 
transplantation performed. 19 The current study 
showed a higher prevalence of BOS in the SLT 
group (SLT 51% vs BLT 33%). Although this 
difference was not significant, the findings are likely 
explained by the fact that 47 of the 50 SLTs were 
done before January 1, 1994, thereby providing at 
least 18 months of follow-up for most of the SLT 
recipients. The 33% prevalence of BOS in the BLT 
group is somewhat lower than the prevalence figures 
we previously reported; however, given that 17 of 
the bilateral transplantation procedures were done 
between January 1, 1994, and December 31, 1994, 
this is likely because of the short duration of fol- 
low-up for more recent recipients of BLT. The 
gradual decline in FEV1 noted in both groups 
beyond 1 year after transplantation (Fig. 2) is prob- 
ably the consequence of BOS. Actuarial survival 
curves for the SLT and BLT groups were similar 
(Fig. 5). Although this study did not show a differ- 
ence between groups in the absolute mortality for 
recipients affected by BOS (SLT 30.4% vs BLT 
28.6%), it is still possible that the trend toward 
better late survival in the BLT group reflects the 
presence of greater "reserve" (i.e., more functional 
lung allograft parenchyma) fter the onset of BOS. 
The high prevalence of BOS 19 and limited sur- 
vival (at 4 years: BLT 73% vs SLT 51%) lend 
support to our belief that lung transplantation 
should be considered only for those patients with 
emphysema who are ideal candidates in every re- 
spect and who have no other therapeutic option. We 
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have reported lung volume reduction surgery to be 
an effective procedure for the relief of dyspnea in 
selected patients with advanced emphysema. 2° We 
have also recently compared a preliminary experi- 
ence with lung volume reduction surgery versus SLT 
and BLT for end-stage mphysema. 21 Other poten- 
tial strategies include the use of unilateral volume 
reduction surgery concomitant with SLT or in a 
staged manner after SLT. 22 Thus it appears that 
volume reduction is a good surgical option that may 
obviate or delay lung transplantation i selected 
patients with emphysema eligible for either proce- 
dure. 
On the basis of the data from the current study, 
we conclude that both SLT and BLT are highly 
satisfactory transplantation ptions in patients with 
emphysema, both of which produce durable results. 
The current analysis has shown that BLT produces a
superior improvement in spirometry and Pa02 val- 
ues and exercise endurance, as well as possibly a 
tendency to better late survival. We conclude that 
the choice of SLT or BLT in end-stage mphysema 
must be individualized to the patient, with particular 
attention paid to their age, body habitus, and phys- 
iologic status. We continue to confine the use of 
SLT to older recipients and to patients with smaller 
body habitus. We prefer the use of BLT in younger 
candidates, in those who are "fit" (other than the 
end-stage lung disease), and in those patients with 
larger body habitus. 
We gratefully acknowledge the help of Richard B. 
Schuessler, PhD, in performing the statistical analysis; 
Carol Cleary for secretarial assistance in preparation of 
the manuscript; and Mary Pohl, Dottie Bigger, Laura 
Ochoa, and Greg Richardson in compiling the data. 
REFERENCES 
1. Pohl MS, Cooper JD. St. Louis International Lung Trans- 
plant Registry results. In: Patterson GA, Couraud L, eds. 
Current opics in general thoracic surgery: lung transplanta- 
tion. Amsterdam: Elsevier, 1995:455-65. 
2. Patterson GA, Cooper JD, Dark JH, et al. Experimental nd 
clinical double-lung transplantation. J Thorac Cardiovasc 
Surg 1988;95:70-4. 
3. Pasque MK, Cooper JD, Kaiser LR, et al. Improved tech- 
nique for bilateral lung transplantation: rationale and initial 
clinical experience. Ann Thorac Surg 1990;49:785-91. 
4. Mal H, Andreassian B, Pamela F, et al. Unilateral lung 
transplantation n endstage pulmonary emphysema. Am Rev 
Respir Dis 1989;140:797-802. 
5. Trulock EP, Egan TM, Kouchoukos NT, et al. Single lung 
transplantation for severe chronic obstructive pulmonary 
disease. Chest 1989;96:738-42. 
6. Yacoub M, Khaghani A, Theodoropoulos S, Tadjkarimi S, 
Banner N. Single-lung transplantation f r obstructive airway 
disease. Transplant Proc 1991;23:1213-4. 
7. Mal H, Sleiman C, Jebrak G, et al. Functional results of 
single-lung transplantation for chronic obstructive lung dis- 
ease. Am J Respir Crit Care Med 1994;149:1476-81. 
8. Levine SM, Anzueto A, Peters JI, et al. Medium term 
functional results of single-lung transplantation f r endstage 
obstructive lung disease. Am J Respir Crit Care Med 1994; 
150:398-402. 
9. Patterson GA, Maurer JR, Williams TJ, Cardoso PG, Scav- 
uzzo M, Todd TR. Comparison of outcomes of double and 
single lung transplantation for obstructive lung disease. J
Thorac Cardiovasc Surg 1991;101:623-32. 
10. Low DE, Trulock EP, Kaiser LR, et al. Morbidity, mortality, 
and early results of single versus bilateral lung transplanta- 
tion for emphysema. J Thorac Cardiovasc Surg 1992;103: 
1119-26. 
11. Bando K, Paradis I, Keenan RJ, et al. Comparison of 
outcomes after single and bilateral lung transplantation for
obstructive lung disease. J Heart Lung Transplant 1995;14: 
692-8. 
12. Sundaresan S, Trachiotis GD, Aoe M, Patterson GA, Cooper 
JD. Donor lung procurement: assessment and operative 
technique. Ann Thorac Surg 1993;56:1409-13. 
13. Cooper JD, Pearson FG, Patterson GA, et al. Technique of 
successful lung transplantation in humans. J Thorac Cardio- 
vasc Surg 1987;93:173-81. 
14. Pasque MK, Cooper JD, Daiser LR, Haydock DA, Triantafil- 
lou A, Trulock EP. Improved technique for bilateral lung 
transplantation: rationale and initial clinical experience. Ann 
Thorac Surg 1990;49:785-91. 
15. Trulock EP. Management of lung transplant rejection. Chest 
1993;103:1566-76. 
16. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser 
LR, Cooper JD. The role of transbronchial lung biopsy in the 
treatment of lung transplant recipients: an analysis of 200 
consecutive procedures. Chest 1992;102:1049-54. 
17. Cooper JD, Billingham ME, Egan T, et al. A working 
formulation for the standardization f nomenclature and for 
clinical staging of chronic dysfunction i  lung allografts. J
Heart Lung Transplant 1993;12:713-6. 
18. Sundaresan S, Semenkovich J, Ochoa L, et al. Successful 
outcome of lung transplantation is ot compromised by the 
use of marginal donor lungs. J Thorac Cardiovasc Surg 
1995;109:1075-80. 
19. Sundaresan S, Trulock EP, Mohanakumar T, Cooper JD, 
Patterson GA. Prevalence and outcome of bronchiolitis 
obliterans syndrome after lung transplantation. Ann Thorac 
Surg 1995;60:1341-7. 
20. Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral 
pneumectomy (volume reduction) for chronic obstructive 
pulmonary disease. J Thorac Cardiovasc Surg 1995;109:106- 
19. 
21. Gaissert HA, Trulock EP, Cooper JD, Sundaresan S, Patter- 
son GA. Comparison of early functional results after volume 
reduction or lung transplantation for chronic obstructive 
pulmonary disease. J Thorac Cardiovasc Surg 1996;111:296- 
307. 
22. Kapelewski DP, Anderson MB, Kirett JM, et al. Volume 
1494 Sundaresan et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1996 
reduction of the native lung after single lung transplantation 
for emphysema. J Thorac Cardiovasc Surg 1996;111:898-9. 
Discussion 
Dr. J. Kent Trinkle (San Antonio, Tex.). Succinctly, the 
big question is this: in patients with emphysema are two 
lungs better than one lung and, if so, under what circum- 
stances? In addition, under what circumstances i the 
larger bilateral operation justified? In the early days of 
lung transplantation, that is, about 10 years ago, when the 
alternative was the en bloc double lung procedure, the 
answer was quite easy: the single lung procedure was 
safer, simpler, and quite effective, and that was an easy 
decision. Today with the bilateral procedure the options 
are a lot closer to call. 
The data from this manuscript are quite clear. From 3 
months to 3 years, BLT has a big advantage over SLT, in 
both FEV 1 and Pao 2 values and exercise tolerance. Al- 
though the mortality data are improved, the difference 
does not quite reach statistical significance. A purist 
would say that the waters are muddied by the selection 
criteria of older, smaller, and sicker patients, with a 
tendency toward more women, and that we need a 
prospective randomized study, but today that is not prac- 
tical or appropriate. 
I would like to introduce one question that refers to 
patients with SLT, and that is the question of right versus 
left lung transplantation, because there is an interesting 
mechanical principle involved. The left diaphragm does 
not have a liver underneath it and so it is more easily 
displaced inferiorly during expiration. The first SLT op- 
eration that I did for chronic obstructive pulmonary 
disease was done in January 1988. I thought I was plowing 
new ground. I did not know that Dr. Mal and his 
colleagues in Paris had done this several months earlier. 
However, I did the procedure on the left side, and the 
transplanted lung looked pathetically small on the plain 
x-ray film, while on the expiratory film it was virtually a 
whiteout, with tremendous mediastinal shift. I did three 
transplantation procedures in a row on the left side with 
the same kind of results, and then I did three on the right 
side and did not see this horrible mediastinal shift on 
expiration, and the FEV 1 findings were dramatically bet- 
ter with the percentage increase almost wice as great in 
the patients in whom we did the right lung transplanta- 
tions because of chronic obstructive pulmonary disease. 
Therefore we developed a simplistic principle that the big 
lung should go on the left, and in the case of chronic 
obstructive pulmonary disease the big lung is the native or 
emphysematous l ng. 
I am sure the current data answer this question much 
better than I did because we stopped doing left SLT 
procedures early on, except for selected anatomic or 
reoperation reasons. The one question that I think the 
authors could answer to add to our knowledge, then, 
would be whether in SLT the procedure should be done 
on the left or the right. 
Dr. Sundaresan. I think the rationale that you give for 
preferring to do right SLT for emphysema makes perfect 
sense. Your center has indeed published data showing 
better objective improvement in those parameters after 
right SLT compared with left SLT. Essentially in our study 
we had a roughly equal distribution of right and left SLT 
procedures for obstructive lung disease. We did not, 
however, subanalyze those two groups to compare those 
outcomes. I agree that that would make an interesting 
study in itself. 
Dr. Magdi Yacoub (London, England). About 2 years 
ago we presented a similar series to the International 
Society of Heart and Lung Transplantation. However, we 
were comparing heart/lung transplantation with SLT for 
emphysema. We found exactly what these authors did in 
that, although the pattern of survival initially and during 
the first 5 years was almost identical for heart/lung trans- 
plantation and SLT for emphysema, the heart/lung trans- 
plant recipients had better espiratory function, better gas 
exchange, better exercise capacity, and a lower prevalence 
of obliterative bronchiolitis. Notably, despite the so-called 
denervation of the heart in these patients, their exercise 
capacity was superior to that in patients with SLT. The 
pattern of survival also tended to improve late. We 
ascribed that to a degree of induced specific immune 
tolerance. Whether heart/lung versus double lung trans- 
plantation contributes something that is better is another 
point that needs to be addressed. 
Dr. Sundaresan. In response to Dr. Yacoub's remarks, 
I would say that in our experience we have analyzed our 
lung transplant recipients to document the prevalence of 
the problem of BOS and have found that it seems to affect 
recipients of single and bilateral procedures equally, and, 
in fact, affects all subgroups of our recipients equally 
without regard for diagnosis, and I think in this study we 
ultimately showed an equal development of obliterative 
bronchiolitis in the late survivors. Survival did not differ 
substantially between our two groups. I think that the 
problems of donor allocation in this country would prob- 
ably not really permit more widespread use of heart/lung 
transplantation in obstructive lung disease. 
Dr. Alvaro Montoya (Chicago, Ill.). About 3 years ago 
we reported our experience at Loyola with BLT versus 
SLT and we found the same results that the group from St. 
Louis just presented. I was always an advocate of BLT. My 
problem is the indication for emphysema. The shortage of 
donors is well known, and expending two lungs in a 
patient with emphysema might not be that good of an 
idea, except in patients younger than 40 years old. 
I have two questions for Dr. Sundaresan. What about 
considering an SLT on one side and a lung reduction on 
the other? Do you have any experience with this proce- 
dure? Second, I am curious as to why the average length 
of stay in the hospital was more than 20 days. In our 
experience patients undergoing lung transplantation for 
emphysema did not spend more than 10 days in the 
hospital. 
Dr. Sundaresan. Regarding SLT concomitant with vol- 
ume reduction operation, there are some reports of that 
combined procedure merging now. We have experience 
with only one such case, which was done within the past 
few weeks. I therefore do not have any long-term data on 
which to base a comment about the suitability of that 
combination. 
As to why the average length of stay in this series was 
more than 20 days in both groups, I think one has to keep 
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in mind that this study looked at patients who underwent 
transplantation as early as 1988. Since then our postoper- 
ative care has evolved, and in general we have streamlined 
the care of these patients o that now the patient with 
uncomplicated emphysema usually does indeed go home 
from the hospital before 10 days after the operation. Thus 
our longer length of stay includes a fairly long length of 
stay for some of the earlier patients in this series. 
Dr. Thomas M. Egan (Chapel Hill, N.C.). Every day in 
the United States one patient on the lung transplantation 
waiting list dies. I commend your efforts to use marginal 
donors for BLT because these are donors who might not 
be used otherwise. If you have a good donor with two 
good lungs, do you do two SLTs or do you do a BLT for 
emphysema? 
Dr. Sundaresan. It has to be individualized to the 
recipient. However, if the recipient who is a candidate for 
those lungs is a young, fit patient, perhaps with ct 1- 
antitrypsin deficiency, we would do a bilateral transplant 
on that patient as opposed to splitting the lung block and 
operating on two older patients with chronic obstructive 
pulmonary disease. 
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